Bioventus Inc. (NYSE:BVS) Shares Sold by Stephens Inc. AR

Stephens Inc. AR lessened its stake in Bioventus Inc. (NYSE:BVS) by 55.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,975 shares of the company’s stock after selling 14,800 shares during the period. Stephens Inc. AR’s holdings in Bioventus were worth $110,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Tower Research Capital LLC TRC boosted its stake in shares of Bioventus by 106.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company’s stock worth $36,000 after buying an additional 1,786 shares during the period. GAMMA Investing LLC boosted its stake in shares of Bioventus by 3,228.7% during the first quarter. GAMMA Investing LLC now owns 5,792 shares of the company’s stock worth $53,000 after buying an additional 5,618 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in shares of Bioventus during the fourth quarter worth about $75,000. Quantbot Technologies LP acquired a new stake in shares of Bioventus during the fourth quarter worth about $103,000. Finally, Sherbrooke Park Advisers LLC acquired a new stake in shares of Bioventus during the fourth quarter worth about $111,000. Institutional investors and hedge funds own 62.94% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Craig Hallum set a $15.00 price objective on shares of Bioventus and gave the company a “buy” rating in a research report on Wednesday, May 7th. Cantor Fitzgerald assumed coverage on shares of Bioventus in a research report on Monday, July 7th. They issued an “overweight” rating and a $12.00 price objective for the company.

Bioventus Trading Down 3.5%

Shares of BVS opened at $6.26 on Monday. The stock has a market cap of $514.22 million, a price-to-earnings ratio of -10.26 and a beta of 0.84. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. Bioventus Inc. has a 1-year low of $6.02 and a 1-year high of $14.38. The firm has a 50 day simple moving average of $6.69 and a 200-day simple moving average of $8.33.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.